Is pulmonary hypertension a metabolic disease?

American Journal of Respiratory and Critical Care Medicine

Volumn 190, Issue 9, 2014, Pages 973-975

  Barnes, Jarrod ^a   Dweik, Raed A ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; CERAMIDE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LEPTIN; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE KINASE 1; SPHINGOSINE KINASE 2; LYSOPHOSPHOLIPID; PHOSPHOTRANSFERASE; SPHINGOSINE; SPHINGOSINE 1-PHOSPHATE; SPHINGOSINE KINASE;

ANGIOGENESIS; APOPTOSIS; CANCER CELL; CANCER GROWTH; CELL CYCLE ARREST; CELL PROLIFERATION; CELL SURVIVAL; EDITORIAL; GLUCOSE TRANSPORT; HEART RIGHT VENTRICLE FAILURE; HEREDITY; HUMAN; INSULIN RESISTANCE; LIPID METABOLISM; LUNG BLOOD VESSEL; LUNG VASCULAR RESISTANCE; METABOLIC DISORDER; NONHUMAN; PATHOGENESIS; PH; PHENOTYPE; PRIORITY JOURNAL; PROTEIN HOMEOSTASIS; PROTEIN METABOLISM; PULMONARY HYPERTENSION; VASCULAR REMODELING; ANALOGS AND DERIVATIVES; ANIMAL; HYPERTENSION, PULMONARY; MALE; PHYSIOLOGY;

ANIMALS; HUMANS; HYPERTENSION, PULMONARY; LYSOPHOSPHOLIPIDS; MALE; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); SPHINGOSINE;

EID: 84922392063     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201409-1702ED     Document Type: Editorial

References (20)

1. Dweik RA, Rounds S, Erzurum SC, Archer S, Fagan K, Hassoun PM, Hill NS, Humbert M, Kawut SM, Krowka M, et al.; ATS Committee on Pulmonary Hypertension Phenotypes. An official American Thoracic Society Statement: pulmonary hypertension phenotypes. Am J Respir Crit Care Med 2014;189:345-355.
2. Morrell NW, Archer SL, Defelice A, Evans S, Fiszman M, Martin T, Saulnier M, Rabinovitch M, Schermuly R, Stewart D, et al. Anticipated classes of new medications and molecular targets for pulmonary arterial hypertension. Pulm Circ 2013;3:226-244.
3. Tonelli AR, Arelli V, Minai OA, Newman J, Bair N, Heresi GA, Dweik RA. Causes and circumstances of death in pulmonary arterial hypertension. Am J Respir Crit Care Med 2013;188:365-369.
4. Pullamsetti SS, Schermuly R, Ghofrani A, Weissmann N, Grimminger F, Seeger W. Novel and emerging therapies for pulmonary hypertension. Am J Respir Crit Care Med 2014;189:394-400.
5. Guignabert C, Tu L, Le Hiress M, Ricard N, Sattler C, Seferian A, Huertas A, Humbert M, Montani D. Pathogenesis of pulmonary arterial hypertension: lessons from cancer. Eur Respir Rev 2013;22:543-551.
6. 18F-fluorodeoxyglucose positron emission tomography for diagnosis and monitoring of pulmonary arterial hypertension. Am J Respir Crit Care Med 2012;185:670-679.
7. Xu W, Koeck T, Lara AR, Neumann D, DiFilippo FP, Koo M, Janocha AJ, Masri FA, Arroliga AC, Jennings C, et al. Alterations of cellular bioenergetics in pulmonary artery endothelial cells. Proc Natl Acad Sci USA 2007;104:1342-1347.
8. Aytekin M, Tonelli AR, Farver CF, Feldstein AE, Dweik RA. Leptin deficiency recapitulates the histological features of pulmonary arterial hypertension in mice. Int J Clin Exp Pathol 2014;7:1935-1946.
9. Heresi GA, Aytekin M, Newman J, DiDonato J, Dweik RA. Plasma levels of high-density lipoprotein cholesterol and outcomes in pulmonary arterial hypertension. Am J Respir Crit Care Med 2010;182:661-668.
10. Hansmann G, Wagner RA, Schellong S, Perez VA, Urashima T, Wang L, Sheikh AY, Suen RS, Stewart DJ, Rabinovitch M. Pulmonary arterial hypertension is linked to insulin resistance and reversed by peroxisome proliferator-activated receptor-gamma activation. Circulation 2007;115:1275-1284.
11. Santos M, Reis A, Gonçalves F, Ferreira-Pinto MJ, Cabral S, Torres S, Leite-Moreira AF, Henriques-Coelho T. Adiponectin levels are elevated in patients with pulmonary arterial hypertension. Clin Cardiol 2014;37:21-25.
12. Ma Z, Vosseller K. O-GlcNAc in cancer biology. Amino Acids 2013;45:719-733.
13. Kultti A, Zhao C, Singha NC, Zimmerman S, Osgood RJ, Symons R, Jiang P, Li X, Thompson CB, Infante JR, et al. Accumulation of extracellular hyaluronan by hyaluronan synthase 3 promotes tumor growth and modulates the pancreatic cancer microenvironment. Biomed Res Int 2014;2014:817613.
14. Zhang F, Du G. Dysregulated lipid metabolism in cancer. World J Biol Chem 2012;3:167-174.
15. Aytekin M, Comhair SA, de la Motte C, Bandyopadhyay SK, Farver CF, Hascall VC, Erzurum SC, Dweik RA. High levels of hyaluronan in idiopathic pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol 2008;295:L789-L799.
16. Sutendra G, Bonnet S, Rochefort G, Haromy A, Folmes KD, Lopaschuk GD, Dyck JR, Michelakis ED. Fatty acid oxidation and malonyl-CoA decarboxylase in the vascular remodeling of pulmonary hypertension. Sci Transl Med 2010;2:44ra58.
17. Heffernan-Stroud LA, Obeid LM. Sphingosine kinase 1 in cancer. Adv Cancer Res 2013;117:201-235.
18. Plano D, Amin S, Sharma AK. Importance of sphingosine kinase (SphK) as a target in developing cancer therapeutics and recent developments in the synthesis of novel SphK inhibitors. J Med Chem 2014;57:5509-5524.
19. Byun HS, Pyne S, Macritchie N, Pyne NJ, Bittman R. Novel sphingosine-containing analogues selectively inhibit sphingosine kinase (SK) isozymes, induce SK1 proteasomal degradation and reduce DNA synthesis in human pulmonary arterial smooth muscle cells. Medchemcomm 2014;4.
20. Chen J, Tang H, Sysol JR, Moreno-Vinasco L, Shioura KM, Chen T, Gorshkova I, Wang L, Huang LS, Usatyuk PV, et al. The sphingosine kinase 1/sphingosine-1-phosphate pathway in pulmonary arterial hypertension. Am J Respir Crit Care Med 2014;190:1032-1043.